Publikationen (Auszug)
Gillespie I, Chan K, Hsieh S, Schindler C, Cheng W, Chang R, Kap E, Morais E, Duh M, Park S, Ketz M, Jenner S, Boxall N, Kendrick S, Theodore S. Characteristics, Treatment Patterns, and Clinical Outcomes of Chronic Hepatitis B Across 3 Continents: Retrospective Database Study. Adv Ther. 40, 425–444 (2023). Doi: 10.1007/s12325-022-02284-1. PMID: 36350533.
Characteristics, Treatment Patterns, and Clinical Outcomes of Chronic Hepatitis B Across 3 Continents: Retrospective Database Study | SpringerLink
Todenhöfer T, Maas M, Ketz M, Kossack N, Colling C, Qvick B, Stenzl A. Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL) TURB. World J Urol. 2021 Feb 10. Doi: 10.1007/s00345-020-03587-0. Epub ahead of print. PMID: 33569642.
Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB | SpringerLink
Ständer S, Ketz M, Kossack N, Akumo D, Pignot M, Gabriel S, Chavda R. Epidemiology of Prurigo Nodularis compared with Psoriasis in Germany: A Claims Database Analysis. Acta Derm Venereol. 2020 Nov 4;100(18):adv00309. Doi: 10.2340/00015555-3655. PMID: 33021323.
Epidemiology of Prurigo Nodularis compared with Psoriasis in Germany: A Claims Database Analysis – PubMed (nih.gov)
Hupe MC, Hammerer P, Ketz M, Kossack N, Colling C, Merseburger AS. Retrospektive GKV-Versorgungsforschungsstudie über GnRH-Antagonisten/-Agonisten zur initialen Therapie des fortgeschrittenen Prostatakarzinoms – Verordnungsmuster und Krankenhauskosten in Deutschland [Retrospective SHI (Statutory Health Insurances) real-world study on initial GnRH antagonist and agonist therapy for advanced prostate cancer: prescription patterns and hospital costs in Germany]. Aktuelle Urol. 2020 Jun;51(3):275-284. German. Doi: 10.1055/a-1018-1651. Epub 2019 Nov 19. PMID: 31745962.
[Retrospective SHI (Statutory Health Insurances) real-world study on initial GnRH antagonist and agonist therapy for advanced prostate cancer: prescription patterns and hospital costs in Germany] – PubMed (nih.gov)
Hupe MC, Hammerer P, Ketz M, Kossack N, Colling C, Merseburger AS. Retrospective Analysis of Patients With Prostate Cancer Initiating GnRH Agonists/Antagonists Therapy Using a German Claims Database: Epidemiological and Patient Outcomes. Front Oncol. 2018 Nov 27;8:543. Doi: 10.3389/fonc.2018.00543. PMID: 30538951; PMCID: PMC6277700.
Retrospective Analysis of Patients With Prostate Cancer Initiating GnRH Agonists/Antagonists Therapy Using a German Claims Database: Epidemiological and Patient Outcomes – PubMed (nih.gov)
Kongressbeiträge (Auszug)
Ständer S, Ketz M, Kossack N, Pignot M, Chavda R, Gabriel S. Clinical and Economic Burden among Patients With Prurigo Nodularis Compared To A Benchmark In Germany: A Real-World-Evidence Claims Data Study. ISPOR Europe 2022, 25st European Congress for Health Economics and Outcome Research (Vienna). 6-9 Nov 2022. Value in Health Journal (December 2022 Volume 25, Issue 12S).
Ständer S, Ketz M, Kossack N, Pignot M, Chavda R, Gabriel S. Disease Burden, Healthcare Resource Utilization & Treatment Pattern among Patients with Prurigo Nodularis compared to a Benchmark in Germany: A Real-World-Evidence Claims Data Study. 31th EADV Congress, European Academy of Dermatology and Venereology (Milan). 7-10 Sept 2022.
Maas M, Stenzl A, Ketz M, Kossack N, Colling C, Qvick B, Todenhöfer T. Retrospective GKV data [Gesetzliche Krankenversicherung (statutory health insurance)] research study on the initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB) – A comparative analysis of costs and urological follow-up therapies using standard white light- (WL-) vs. blue light- (BL-) TURB. ISPOR EUROPE 2019, 22st European Congress for Health Economics and Outcome Research (Kopenhagen). 2-6 Nov 2019. Value in Health Journal (November 2019 Volume 22, Supplement 3, Pages S535). DOI:https://doi.org/10.1016/j.jval.2019.09.694.
Chavda R, Gabriel S, Pignot M, Ketz M, Medina P, Alessandrini E, Amri I, Ständer S. Epidemiology of prurigo nodularis among SHI-insured patients in Germany: a claims database analysis. 28th EADV Congress, European Academy of Dermatology and Venereology (Madrid). 9-13 Okt 2019.
Todenhöfer T, Maas M, Ketz M, Kossack N, Colling C, Qvick B, Stenzl A. Retrospektive GKV-Analyse von Kosten & urologischen Folgetherapien bei Einsatz der Weißlicht – bzw. Blaulicht -TURB zur Therapie des Blasenkarzinoms. DGU 2019, 71. Kongress der Deutschen Gesellschaft für Urologie e.V. (Hamburg). 18-21 Sept 2019.
Hupe MC, Hammerer P, Ketz M, Kossack N, Colling C, Merseburger AS. Initial therapy for advanced prostate carcinoma (PCa) with GnRH agonist and antagonist (GnRHa) – a retrospective analysis of prescription patterns and hospital costs based on German GKV data [Gesetzliche Krankenversicherung (Statutory Health Insurance)]. ISPOR EUROPE 2018, 21st European Congress for Health Economics and Outcome Research (Barcelona). 10-14 Nov 2018. Value in Health Journal (October 2018 Volume 21, Supplement 3, Pages S30–S31). DOI:https://doi.org/10.1016/j.jval.2018.09.178.
Hupe MC, Hammerer P, Ketz M, Kossack N, Colling C, Merseburger AS. Retrospektive GKV-Versorgungsforschungsstudie über die Therapie des fortgeschrittenen Prostatakarzinoms (PCa) mit GnRH-Antagonisten und -Agonisten (GnRHa) – Eine vergleichende Analyse von Verordnungsmustern und Krankenhaus (KH)-Kosten. DGU 2018, 70. Kongress der Deutschen Gesellschaft für Urologie e.V. (Dresden). 26-29 Sept 2018.
Moennig E, Hadjiyianni I, Otto T, Cao D, De Koven M, Karkare S, Saade P, Ketz M, Baumann T, Perez-Nieves M. Factors associated with treatment persistence among people with Type 2 Diabetes Mellitus (T2DM) initiating basal insulin – real-world data from Germany. Deutscher Diabetes Kongress 2016, 51. Jahrestagung der DDG. 4-7 Mai 2016. Diabetologie und Stoffwechsel 2016; 11 – FV31. DOI: 10.1055/s-0036-1580778.
Dipl.-Ges.-Ök. Miriam Ketz
Leitung Versorgungsforschung
+49 (0)40 – 540 905 40 – 3
Wie können wir Ihnen helfen?
Büro
Heimuder Straße 52
D-20148 Hamburg
info@d-to-d.de
Telefon
+49 (0) 40 - 540 905 40-0